Q2 2026

Filed Aug 7, 2026 · 10-Q · 38 days after period end · 0001339970-26-000053

Q2 2026 · 10-Q

Revenue—

Net Income

-$10.31M

N/M vs Q2 2025

EPS Diluted

-$0.11

N/M vs Q2 2025

Operating Income-$10,881,000N/M

Operating Cash Flowderived-$9,351,000N/M

Same quarter

Metric	Q2 2026	Q2 2025	Q2 2024	Q2 2023
Revenue	—	$0.00	$0.00	$0.00
Net Income	-$10.31M	-$19.53M	-$16.31M	-$12.34M
EPS Diluted	-$0.11	-$0.22	-$0.23	-$0.22

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR